IFNA1 and cancer: A Clever-1-blocking antibody, bexmarilimab (IgG4), activates T-cells and IFN responses in advanced solid cancers and elicits cancer type-dependent disease control alongside few objective responses in a phase 1/2 trial [96, 97].